KALV KalVista Pharmaceuticals Inc
Price (delayed)
$12.21
Market cap
$607.03M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.77
Enterprise value
$444.08M
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary
Highlights
KALV's quick ratio has surged by 150% year-on-year and by 61% since the previous quarter
KALV's equity has surged by 64% year-on-year and by 8% since the previous quarter
KalVista Pharmaceuticals's net income has plunged by 62% YoY and by 12% from the previous quarter
The EPS has contracted by 20% YoY and by 2.2% from the previous quarter
Key stats
What are the main financial stats of KALV
Market
Valuations
Earnings
Shares outstanding
49.72M
Market cap
$607.03M
Enterprise value
$444.08M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.16
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$181.42M
Net income
-$175.87M
EBIT
-$168.78M
EBITDA
-$167.88M
Free cash flow
-$128.18M
Per share
Balance sheet
Liquidity
EPS
-$3.77
EPS diluted
-$3.77
Free cash flow per share
-$2.44
Book value per share
$2.94
Revenue per share
$0
TBVPS
$5.24
Total assets
$275.99M
Total liabilities
$130.87M
Debt
$4.34M
Equity
$145.13M
Working capital
$241.74M
Debt to equity
0.03
Current ratio
10.44
Quick ratio
9.88
Net debt/EBITDA
0.97
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-80.6%
Return on equity
-106.8%
Return on invested capital
-128.1%
Return on capital employed
-67.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KALV stock price
How has the KalVista Pharmaceuticals stock price performed over time
Intraday
-1.93%
1 week
1.92%
1 month
28.12%
1 year
-2.24%
YTD
44.16%
QTD
44.16%
Financial performance
How have KalVista Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$181.42M
Net income
-$175.87M
Gross margin
N/A
Net margin
N/A
KalVista Pharmaceuticals's net income has plunged by 62% YoY and by 12% from the previous quarter
KALV's operating income is down by 47% YoY and by 6% QoQ
Growth
What is KalVista Pharmaceuticals's growth rate over time
Valuation
What is KalVista Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.16
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 20% YoY and by 2.2% from the previous quarter
KALV's equity has surged by 64% year-on-year and by 8% since the previous quarter
The P/B is 63% higher than the 5-year quarterly average of 2.6 and 37% higher than the last 4 quarters average of 3.1
Efficiency
How efficient is KalVista Pharmaceuticals business performance
KalVista Pharmaceuticals's return on equity has decreased by 24% YoY and by 2.8% QoQ
The ROA fell by 11% YoY but it rose by 9% QoQ
KalVista Pharmaceuticals's return on invested capital has decreased by 10% YoY and by 6% QoQ
Dividends
What is KALV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KALV.
Financial health
How did KalVista Pharmaceuticals financials performed over time
KALV's total assets is 111% higher than its total liabilities
KALV's quick ratio has surged by 150% year-on-year and by 61% since the previous quarter
KALV's total assets has soared by 142% YoY and by 72% QoQ
KalVista Pharmaceuticals's debt is 97% lower than its equity
KALV's equity has surged by 64% year-on-year and by 8% since the previous quarter
The debt to equity has plunged by 57% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.